Picoplatin is a platinum-based chemotherapeutic agent, classified as a second-generation platinum compound. It is designed to overcome some of the limitations associated with traditional platinum drugs like cisplatin and carboplatin, particularly in terms of resistance and toxicity. Picoplatin exhibits a unique mechanism of action, primarily through the formation of DNA cross-links, which disrupts DNA replication and transcription, ultimately leading to cancer cell death. Its chemical structure includes a picolinate ligand, which enhances its solubility and bioavailability compared to other platinum compounds. Picoplatin has shown promise in preclinical and clinical studies for treating various types of cancer, including solid tumors and metastatic cancers. Its pharmacokinetics indicate a favorable distribution profile, and it is generally administered intravenously. While it has demonstrated efficacy, ongoing research continues to evaluate its safety profile, optimal dosing regimens, and potential side effects, which may include myelosuppression and nephrotoxicity, similar to other platinum-based therapies. Overall, picoplatin represents a significant advancement in the development of targeted cancer therapies.

Picoplatin

181630-15-9: (SP-4-3)-Amminedichloro(2-methylpyridine)platinum, Amd 473, Amminedichloro(2-methylpyridine)platinium, Nx 473, Platinum(2+) Chloride - 2-Methylpyridine Ammoniate (1:2:1:1), Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-, Zd 0473, Zd0473, Picoplatin

Picoplatin, an anti-cancer agent overcoming platinum resistance, alkylates DNA to block replication, transcription, and induce apoptosis.

CAS 181630-15-9: Picoplatin

Picoplatin

Ref: TM-T21323

Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)-

Ref: IN-DA002306

Picoplatin

Ref: 3D-FP65130

Picoplatin

Ref: 7W-GP0248